arrow
B

Bjørn H. Ebdrup

mental health centre glostrup
H指数:34
被引数:4,847

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Glutamate levels in antipsychotic-free, first-episode psychosis: a 7-tesla MRS study across five brain regions

抗精神病药物未使用的一线精神病发作中谷氨酸水平:一项涵盖五个脑区的7特斯拉MRS研究

2026-09-270
OAAI
The efficacy of ketogenic interventions on neuropsychological & metabolic outcomes in serious mental illness & neurocognitive disorders: a systematic review & meta-analysis

生酮干预对严重精神疾病和神经认知障碍患者神经心理及代谢结局有效性的系统评价与荟萃分析

2026-08-270
OAAI
Fish oil-derived fatty acids during pregnancy and risk of neurodevelopmental disorders in children at age 10 - A randomized controlled trial

孕期鱼油来源脂肪酸与儿童10岁时神经发育障碍风险——一项随机对照试验

2026-07-020
OAAI
Genetic investigation of the association between maternal dietary patterns and offspring ADHD

母体膳食模式与后代ADHD关联的遗传学研究

2026-05-250
OAAI
Local chemoarchitecture explains widespread lower cortical thickness associated with clinical high risk for psychosis

局部化学构筑解释了与精神病临床高风险相关的广泛皮质变薄现象

2026-04-040
PRE
Neonatal gut Bifidobacterium associates with indole-3-lactic acid levels in blood and risk of ADHD at age 10

新生儿肠道双歧杆菌与血液中吲哚-3-乳酸水平及10岁时ADHD风险相关

2026-02-110
OAAI
Longitudinal metabolome profiling from pregnancy through childhood and risk of neurodevelopmental disorders at age 10

从怀孕到儿童期的纵向代谢组分析和10岁时神经发育障碍的风险

2026-01-080
OAAI
Exploring brain structural effects of dopaminergic antagonism and partial agonism in antipsychotic-naïve patients with first-episode psychosis using normative modeling

使用规范模型探索多巴胺能拮抗作用和部分激动作用在首次发作的抗精神病药物治疗患者中的脑结构效应

2026-01-010
PRE
Confirmatory factor analysis of competing PANSS negative symptom models: data from OPTiMiSE first-episode schizophrenia study

竞争性PANSS阴性症状模型的验证性因子分析:OPTiMiSE首次发作精神分裂症研究的数据

2025-12-120
OAAI
Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them

精神分裂症复发: 临床研究标准和国际共识指南的系统评价

2025-11-011
PRE
Structural covariance network topology in individuals at clinical high risk for psychosis: the ENIGMA-CHR Study

精神分裂症临床高风险个体中的结构协方差网络拓扑:ENIGMA-CHR研究

2025-10-220
OA
Alleviating negative symptoms in schizophrenia using a virtual reality-based therapy targeting social reward learning (ENGAGE): Protocol for a randomised, controlled, assessor-blind pilot study

通过基于虚拟现实的社会奖励学习疗法缓解精神分裂症阴性症状(ENGAGE):一项随机、对照、评估者盲法的试点研究方案

2025-10-080
PRE
Interrelations between dopaminergic-, gabaergic- and glutamatergic neurotransmitters in antipsychotic-naïve psychosis patients and the association to initial treatment response

多巴胺能、GABA能和谷氨酸能神经递质之间的相互关系,在未使用抗精神病药物的精神病患者的初治反应中的关联

2025-09-120
OAAI